Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.

ABSTRACT: With the increasing prevalence of diabetes, the incidence rate of diabetic kidney disease (DKD) has risen yearly in China. While traditional therapies like renin-angiotensin system blockers remain foundational, the treatment paradigm is rapidly evolving with the emergence of novel agents, including SGLT2 inhibitors, mineralocorticoid antagonists, endothelin receptor antagonists, and GLP-1 receptor agonists. This study aims to provide an overview of the changing landscape of drug clinical trials on DKD in mainland China from 2013 to 2023. Detailed information of drug trials for DKD registered on the National Medical Products Administration Registration and Information Disclosure Platform for Drug Clinical Studies was collected. A total of 50 trials for DKD were included. Bioequivalence tria

SUBMITTER: Yang Y 

PROVIDER: S-EPMC12927394 | biostudies-literature | 2026 Dec

REPOSITORIES: biostudies-literature